Stockscreener 앱 받기
36.97
3.52%
-1.35
시간 외 거래:
36.63
-0.34
-0.92%
전일 마감가:
$38.32
열려 있는:
$37.97
하루 거래량:
3.36M
Relative Volume:
1.31
시가총액:
$6.03B
수익:
$264.79M
순이익/손실:
$-14.36M
주가수익비율:
-336.09
EPS:
-0.11
순현금흐름:
$-28.11M
1주 성능:
-3.75%
1개월 성능:
-14.00%
6개월 성능:
+51.70%
1년 성능:
+168.29%
1일 변동 폭
$36.36
$40.19
1주일 범위
$36.36
$40.19
52주 변동 폭
$12.93
$43.32
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
36.97 | 6.03B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
Where are the Opportunities in (TGTX) - news.stocktradersdaily.com
Exploring US High Growth Tech Stocks - simplywall.st
TG Therapeutics: Progress In MS Tempered By High Expectations (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by LPL Financial LLC - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment By Investing.com - Investing.com South Africa
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why - MSN
TG Therapeutics Shares Rise Almost 30% In 3 Months: Here's Why - Barchart.com
TGTX: Promising Short Squeeze Opportunity with Biopharma Focus - GuruFocus
TG Therapeutics (TGTX) Highlights New Research on BRIUMVI® for M - GuruFocus
TG Therapeutics (TGTX) Struggles with Low ROE Despite High Debt - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential - Stock Titan
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
TG Therapeutics (TGTX) Shares Jump Amid Strong Briumvi Sales - GuruFocus
TG Therapeutics (TGTX) Highlights BRIUMVI® Data at Neurology Mee - GuruFocus
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet? - simplywall.st
TG Therapeutics showcases BRIUMVI data at neurology meet - Investing.com
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile - Stock Titan
TG Therapeutics reports on MS treatment switch By Investing.com - Investing.com South Africa
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewswire
TG Therapeutics reports on MS treatment switch - Investing.com
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short - Stock Titan
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - MSN
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com India
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):